Literature DB >> 8097064

Platelet factor XIII becomes active without the release of activation peptide during platelet activation.

L Muszbek1, J Polgár, Z Boda.   

Abstract

The potentially active A subunit of factor XIII of blood coagulation has also been detected in platelets and monocytes/macrophages through the exact function of this cellular protransglutaminase has not yet been elucidated. In physiological conditions the first step in the activation of plasma factor XIII is the removal of an activation peptide from the N-terminal end of subunit A by thrombin. The A subunit then, in the presence of Ca2+, dissociates from the inhibitory B subunit and assumes an active conformation. Cellular factor XIII, which lacks B subunit, can be proteolytically activated in vitro by thrombin and the intracellular Ca2+ sensitive protease, calpain, in the same way as plasma factor XIII subunit A, and calpain has been suggested as the intracellular protease involved in the activation of cellular factor XIII in platelets. In the present experiments it was shown by SDS PAGE that during long-term stimulation of platelets with thrombin nondisulfide-crosslinked high M(r) protein polymers not penetrating the concentrating gel were formed. The lack of these polymers in thrombin-stimulated factor XIII deficient platelets clearly indicated that their formation in normal platelets was due to factor XIII that became active during platelet activation. However, no release of the activation peptide could be detected by Western blotting during this process. Similarly, no proteolytic cleavage of factor XIII was detectable when platelets were stimulated by Ca2+ ionophore through this stimulus activated calpain as it was clearly demonstrated by the breakdown of major intracellular calpain substrates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097064

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

Review 2.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Reversible activation of cellular factor XIII by calcium.

Authors:  Gunhild Klarskov Kristiansen; Mette Dahl Andersen
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

4.  Activation of factor XIII is accompanied by a change in oligomerization state.

Authors:  Boris A Anokhin; Vilius Stribinskis; William L Dean; Muriel C Maurer
Journal:  FEBS J       Date:  2017-10-03       Impact factor: 5.542

5.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

6.  Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

Authors:  Anna D Protopopova; Andrea Ramirez; Dmitry V Klinov; Rustem I Litvinov; John W Weisel
Journal:  J Thromb Haemost       Date:  2019-03-14       Impact factor: 5.824

7.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

Review 8.  Regulation of the activities of the mammalian transglutaminase family of enzymes.

Authors:  Cornelius Klöck; Chaitan Khosla
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

9.  Functional factor XIII-A is exposed on the stimulated platelet surface.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Steven R Fraser; Claire S Whyte; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

10.  Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.

Authors:  Huriye Ercan; Lisa-Marie Mauracher; Ella Grilz; Lena Hell; Roland Hellinger; Johannes A Schmid; Florian Moik; Cihan Ay; Ingrid Pabinger; Maria Zellner
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.